Interestingly, the percentage of the Mon1 subset was found to be lower in NAFLD patients and, while Zhang et al. described an increase in the Mon2 fraction, Wang et al. documented a higher Mon3 fraction in patients with NAFLD [73,74]. This evidence concerns the gene MON2 and metabolic dysfunction-associated steatotic liver disease.